Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Cheryl Galt who wrote (28916)	6/22/1999 5:05:00 PM
From: J Stone	Read Replies (2) \| Respond to of 32384

Cheryl, It will surely be one of management's biggest screw ups if they fail to complete the filing by June 30. That said, their track record in terms of meeting targeted dates has been weak. I suspect that larger investors are awaiting filing confirmation before taking any action. My suspicion lies in the weak volume we've experience over the past several weeks. Targretin's passing FDA approval is key on the "march to profitability." I still believe it was get fast track status when it is filed. FWIW Jeff

To: Cheryl Galt who wrote (28916)	6/23/1999 8:18:00 AM
From: Louis A. Rawden	Read Replies (1) \| Respond to of 32384

Having been an Athena Nureosciences investor I am always suspicious when ELN gets involved with a company.....With the recent BIO tech takeover activity If someone had their eyes on LGND I would think announcing just before July 22 would save them 20 to 25 million in purchase price.....the weeks prior to July 22 should be interesting.